Anti-VEGF Agents: Changing the Treatment Landscape for Diabetic Retinopathy

Article Figures & Data

Figures

  • Figure 1.

    Mean Change in Visual Acuity

    p values for difference in mean change in visual acuity from sham+prompt laser at the 52-week visit: ranibizumab+prompt laser < .001; ranibizumab+deferred laser < .001; and triamcinolone+prompt laser = .31.Reproduced from Diabetic Retinopathy Clinical Research Network. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology 2010; 117(6):1064–1077. With permission from Elsevier.*On November 21, 2014, this was changed from Sharm to Sham.